Laparoscopic Heller Myotomy for Achalasia: Surgical Technique, POEM Comparison, and Outcomes — Cost, Top Hospitals & Success Rates | MyMedicPlus

Laparoscopic Heller myotomy (LHM) is the established surgical gold-standard treatment for achalasia, a rare but chronic esophageal motility disorder in which defective lower esophageal sphincter (LES) relaxation and absent peristalsis prevent food and liquid from passing normally into the stomach. The procedure involves a precise longitudinal division of the muscular fibers of the distal esophagus and proximal stomach — the myotomy — which permanently relieves the functional obstruction at the gastroesophageal junction.

The myotomy extends 6 cm on the esophagus (above the gastroesophageal junction) and 2–3 cm onto the gastric cardia below it, totaling at least 8 cm. This length is critical: extension onto the stomach addresses the unique high-pressure zone at the cardia and prevents incomplete myotomy, the leading cause of surgical failure. All layers of the muscularis propria — the inner circular and outer longitudinal muscle layers — are divided under direct vision, exposing the underlying esophageal mucosa, which should visibly bulge outward when the myotomy is complete.

Because LES division eliminates the anti-reflux barrier, a partial fundoplication is added to reduce postoperative gastroesophageal reflux disease (GERD). Either a Dor anterior 180-degree fundoplication — which covers the exposed mucosa as a protective flap and reduces perforation risk — or a Toupet posterior 270-degree fundoplication — which provides superior reflux control in some randomized series — is used. A complete 360-degree Nissen wrap is deliberately avoided, as it would recreate outflow obstruction in an already aperistaltic esophagus.

The laparoscopic approach uses 4–5 ports and provides equivalent symptom relief to open thoracic or abdominal Heller myotomy with substantially shorter hospitalization, less pain, and faster return to normal activity. Robotic-assisted LHM is increasingly performed, with the robotic platform's precision suturing capabilities particularly valued during the delicate dissection at the gastroesophageal junction where mucosal perforation risk is highest.

Laparoscopic Heller myotomy is primarily indicated for achalasia, classified using the Chicago Classification of Esophageal Motility Disorders, version 4.0 (CCv4.0), which defines three subtypes based on high-resolution manometry patterns:

• Type I Achalasia (Classic): Absent peristalsis with minimal esophageal pressurization. Responds well to LHM, POEM, and pneumatic dilation.
• Type II Achalasia (with Esophageal Pressurization): Absent peristalsis with panesophageal pressurization in at least 20% of swallows. The subtype with the best response to all therapies, including LHM (success rate above 90%).
• Type III Achalasia (Spastic): Absent peristalsis with premature or spastic contractions in at least 20% of swallows. The most difficult subtype to treat; POEM is preferred over LHM for type III because it allows a longer myotomy extending into the esophageal body to address spastic segments.

Other esophageal motility disorders that may be addressed by myotomy include:

• Esophagogastric junction outflow obstruction (EGJOO): Elevated integrated relaxation pressure (IRP) with preserved peristalsis on high-resolution manometry; LHM is considered after exhausting less invasive treatments if symptoms are severe
• Jackhammer esophagus with a structural (non-pharmacologically responsive) high-amplitude component at the gastroesophageal junction

Symptom severity is quantified using the Eckardt score (range 0–12), assessing dysphagia, regurgitation, retrosternal chest pain, and weight loss, each rated 0–3. An Eckardt score above 3 defines symptomatic achalasia requiring intervention. A postoperative score of 3 or below defines clinical success. The majority of patients present with scores of 6–10 at diagnosis, reflecting moderate to severe disease burden with significant impact on nutritional status and quality of life.

Patient selection for laparoscopic Heller myotomy requires confirmation of the achalasia diagnosis, subtype classification, and assessment of the patient's physiological fitness for laparoscopic surgery under general anesthesia.

Diagnostic workup before LHM:

• High-resolution esophageal manometry (HREM) — mandatory for achalasia diagnosis and subtype classification per CCv4.0. Defines integrated relaxation pressure (IRP) and peristaltic pattern.
• Timed barium esophagogram — quantifies esophageal emptying; a column height above 5 cm at 5 minutes indicates functional obstruction
• Upper GI endoscopy (EGD) — excludes pseudoachalasia from malignancy (particularly gastric cardia or esophageal adenocarcinoma), identifies esophageal candidiasis from food stasis, and assesses mucosal integrity
• CT chest/abdomen — when pseudoachalasia is suspected (age above 60, rapid weight loss, short symptom duration) to exclude mediastinal or subdiaphragmatic malignancy

Ideal surgical candidates:

• Patients with confirmed achalasia type I or II with Eckardt score above 3 who prefer surgical treatment over repeated endoscopic dilation or POEM
• Those who have failed or partially responded to pneumatic balloon dilation (PBD) — two or more sessions without durable improvement
• Patients with type III achalasia preferring surgery, though POEM may achieve longer myotomy more easily in this subtype
• Individuals with sigmoid-shaped megaesophagus (tortuosity but not end-stage dilatation) where surgery is appropriate
• ASA class I–III patients with adequate cardiopulmonary reserve for general anesthesia and pneumoperitoneum

Relative contraindications:

• End-stage sigmoid megaesophagus (esophageal diameter above 6–8 cm with extreme tortuosity) — esophagectomy may be more appropriate
• Prior fundoplication or extensive esophageal or gastric surgery creating prohibitive adhesions
• Severe pulmonary disease making general anesthesia prohibitively high risk
• Confirmed pseudoachalasia from underlying malignancy — treat the primary tumor first

Laparoscopic Heller myotomy is performed under general anesthesia in the supine or modified lithotomy position with the patient in 30-degree reverse Trendelenburg to allow the stomach and liver to fall away from the operative field.

Port configuration:

• 10–12 mm umbilical or supraumbilical port for the 30-degree laparoscopic camera
• Two 5 mm ports in the left and right upper quadrants for dissection and retraction instruments
• 5 mm epigastric port for liver retraction (Nathanson liver retractor preferred)
• Optional 5 mm left lateral port for assistant instruments

Dissection and myotomy: The phrenoesophageal ligament is divided, the gastroesophageal fat pad is resected to expose the GEJ, and the distal 6 cm of esophagus and proximal 2–3 cm of gastric cardia are cleared of overlying fat. The myotomy begins 3–4 cm above the GEJ using hook electrocautery or harmonic energy device, extending distally across the GEJ and 2–3 cm onto the stomach. Maintaining the plane between the longitudinal and circular muscle layers is critical to avoid mucosal entry. The adequacy of myotomy is confirmed when the mucosal bulge is visible across the full myotomy length and intraoperative endoscopy shows absence of LES resistance.

Fundoplication: After myotomy, a partial wrap is added:

• Dor anterior fundoplication: The gastric fundus is folded anteriorly over the myotomy site and sutured to the cut edges of muscle with 2-0 non-absorbable sutures, covering exposed mucosa
• Toupet posterior fundoplication: The gastric fundus is passed behind the esophagus and sutured to the right and left myotomy edges, providing a 270-degree posterior wrap with superior pH control in some randomized series

Robotic-assisted LHM: The da Vinci robotic platform is particularly advantageous for Heller myotomy because the GEJ dissection requires precise tremor-free movements in a confined space. The 10× magnification facilitates identification of the thin mucosal layer and reduces the risk of inadvertent mucosal entry, which occurs in approximately 5–10% of conventional laparoscopic cases.

Laparoscopic Heller myotomy offers sustained symptom relief and high patient satisfaction as the definitive surgical treatment for achalasia, with a well-established evidence base accumulated over more than 30 years of practice.

• High clinical success rates: 85–95% of patients with achalasia type I and II achieve an Eckardt score of 3 or below at one year. Type II achalasia has the highest response rate (above 90%) across all achalasia therapies
• Durable relief: Long-term follow-up data (5–10 years) show sustained symptom control in approximately 75–85% of patients, superior to pneumatic dilation (50–70% at 5 years) and without the reflux burden of POEM
• Superior reflux protection compared with POEM: The IPOEM RCT (Lancet, 2023) demonstrated that LHM with Dor fundoplication resulted in pathological GERD on 24-hour pH monitoring in 23% of patients versus 41% after POEM — a clinically important distinction for long-term esophageal mucosal health
• Minimally invasive advantages: Short hospitalization (1–3 days), low wound complication rate (under 2%), and return to normal activity within 2 weeks compared with 4–6 weeks after open Heller myotomy
• No radiation exposure: Unlike timed barium studies repeated during follow-up, the surgical intervention itself does not involve ionizing radiation
• One-time definitive treatment: Unlike pneumatic dilation, which requires repeat sessions in up to 50% of patients within 5 years, LHM typically provides sustained relief without the need for re-intervention in the majority of patients
• Simultaneous fundoplication: Adding partial fundoplication at the time of myotomy prevents the progression to symptomatic GERD and its long-term sequelae (Barrett's esophagus, stricture)

Laparoscopic Heller myotomy is generally safe in experienced esophageal surgical centers, but specific technical complications and functional risks must be discussed during preoperative informed consent.

Intraoperative complications:

• Esophageal or gastric mucosal perforation (5–10%): the most common intraoperative complication, occurring during myotomy at the GEJ where the mucosa is thinned and closely adherent to muscle. Recognized immediately by endoscopy and repaired with interrupted 3-0 absorbable sutures; Dor fundoplication covers the repair. Unrecognized perforations cause postoperative mediastinitis or peritonitis requiring urgent re-operation.
• Inadvertent vagal nerve injury causing gastroparesis or diarrhea; minimized with meticulous nerve identification
• Splenic capsular tear from retraction — rarely requires splenectomy

Early postoperative complications:

• Leak from repaired mucosal perforation (under 1% with recognized and repaired intraoperative perforation)
• Dysphagia from fundoplication wrap too tight or myotomy too short — usually apparent within 4–6 weeks, managed with dilation or re-operation

Late functional complications:

• Gastroesophageal reflux disease: despite partial fundoplication, pathological reflux (pH study-confirmed) occurs in 23% after LHM versus 41% after POEM (IPOEM RCT). Managed with long-term PPI therapy in most cases
• Treatment failure or recurrence (10–20% at 5–10 years): incomplete myotomy, fibrosis at myotomy site, or progression of esophageal disease. Reassessed with manometry and barium esophagogram; salvage options include repeat myotomy, POEM, or esophagectomy for end-stage disease
• Barrett's esophagus: uncontrolled long-term reflux in non-compliant patients may lead to columnar metaplasia — reinforcing the rationale for adding anti-reflux fundoplication at the time of myotomy

General surgical risks: DVT, pulmonary embolism, pneumonia, port-site hernia, and anesthesia-related complications. Overall mortality is under 0.1% in elective cases at high-volume esophageal surgery centers.

A structured postoperative recovery plan and long-term surveillance protocol are essential for monitoring treatment success, identifying complications, and managing reflux after Heller myotomy.

Immediate postoperative care:

• Clear liquid diet commenced the evening of surgery (day 0–1); advanced to full liquids on day 1–2, and to a soft mechanical diet by day 3–5
• Hospital discharge typically on postoperative day 1–3
• Nasogastric tube is generally not routinely placed; if used intraoperatively, it is removed before the patient awakens
• Proton pump inhibitor (PPI) therapy (omeprazole 20–40 mg or equivalent) initiated postoperatively and continued for a minimum of 6–8 weeks; long-term PPI use guided by 24-hour pH monitoring results

Outpatient follow-up protocol:

• Week 2–4: Eckardt score reassessment; dietary counselling to advance from soft to normal diet; wound check
• Month 3: Timed barium esophagogram (upright column height at 1 and 5 minutes) to confirm esophageal emptying improvement; Eckardt score documentation
• Month 6: 24-hour ambulatory pH monitoring to quantify acid exposure and guide long-term PPI use; high-resolution manometry if dysphagia persists
• Year 1 and annually: Eckardt score assessment; upper endoscopy every 3–5 years for surveillance of esophageal mucosa and Barrett's esophagus screening in patients with confirmed GERD

Dietary guidance:

• Thorough chewing of all food, especially meats and dense bread; small bites and upright posture during meals
• Avoidance of large bolus meals, carbonated drinks, and lying down within 2 hours of eating
• Gradual advancement from soft to normal diet over 4–6 weeks, guided by symptom tolerance

Patients with residual or recurrent dysphagia should be re-evaluated with manometry and barium esophagogram before any re-intervention, as obstructive symptoms may reflect fundoplication wrap tightness rather than incomplete myotomy.

The cost of laparoscopic Heller myotomy varies substantially based on geographic region, hospital tier, surgical approach (laparoscopic vs. robotic), and whether the procedure is performed in an inpatient or same-day surgical setting.

Estimated cost ranges by country:

• United States: $15,000–$28,000 (inpatient, including surgeon, anesthesia, and facility fees)
• United Kingdom (private): £7,000–£15,000
• India: $2,500–$5,500 at JCI or NABH-accredited hospitals
• Thailand: $4,000–$8,000
• Singapore: $7,000–$15,000
• Turkey: $3,000–$6,500
• Germany: €7,000–€14,000

Key cost determinants:

• Surgical platform: Robotic-assisted LHM adds $2,000–$4,000 to procedure costs via robotic arm fees and disposable EndoWrist instruments; justified in centers where robotic precision is associated with lower mucosal perforation rates
• Preoperative diagnostics: High-resolution manometry ($500–$1,500), timed barium esophagogram, and upper endoscopy add to the total episode cost; bundled pricing at specialized esophageal centers may include these
• Hospital accreditation and tier: Academic esophageal surgery centers command higher institutional fees but offer higher case volumes and subspecialty expertise associated with better outcomes
• Surgeon subspecialty: Thoracic or upper GI esophageal surgeons with dedicated achalasia practices — in whom LHM mucosal perforation rates are typically below 3% — charge premium fees reflecting training and volume
• Anesthesia complexity: Double-lumen endotracheal tube or OLV is rarely required for purely laparoscopic cases but may add cost in thoracic surgery hybrid settings
• Length of stay: Same-day discharge is practiced in select centers for uncomplicated cases; inpatient stay of 1–3 days is standard

Medical travel for LHM to India or Thailand can reduce out-of-pocket costs by 70–80% compared with US private-pay pricing. Patients should confirm the surgical team's achalasia case volume and verify whether robotic or standard laparoscopic technique will be used before booking.

Achalasia is a chronic condition requiring long-term management. Several evidence-based treatment alternatives to laparoscopic Heller myotomy exist, and the optimal choice is informed by achalasia subtype (CCv4.0 classification), symptom severity, patient preference, and institutional availability.

Peroral Endoscopic Myotomy (POEM): The most significant endoscopic advancement for achalasia. POEM involves creating a submucosal tunnel through an upper endoscope, through which the inner circular muscle layer is divided from the mid-esophagus into the gastric cardia. The IPOEM RCT (Lancet, 2023) found comparable clinical success rates to LHM (83% vs. 81% at 2 years) but significantly higher pathological GERD on pH monitoring (41% vs. 23%). POEM is particularly advantageous for type III (spastic) achalasia, where the myotomy can be extended higher into the esophageal body to address spastic segments — a technically simpler maneuver endoscopically than laparoscopically. POEM avoids abdominal surgery entirely but provides no anti-reflux protection, requiring long-term PPI therapy in most patients.

Pneumatic balloon dilation (PBD): An endoscopic procedure in which a graded balloon (30 mm, 35 mm, then 40 mm) is inflated under fluoroscopic guidance to mechanically disrupt the LES fibers. Technical success is high, but long-term efficacy is inferior to LHM — durable response at 5 years is 50–70%, requiring repeat sessions in up to 50% of patients. A esophageal perforation risk of 1–2% per session requires access to surgical backup. PBD is first-line in centers without LHM or POEM expertise, and for patients with high surgical risk.

Botulinum toxin injection (Botox): Endoscopic injection of botulinum toxin A into the LES temporarily paralyses circular muscle fibers. Symptom relief is achieved in approximately 65–80% of patients initially but is short-lived — effect wanes within 6–12 months in most patients. Botox is reserved for elderly patients or those with significant comorbidities where definitive intervention carries unacceptable surgical risk, and as a bridge to surgery.

Esophagectomy: Reserved for end-stage achalasia with a massively dilated, sigmoid-shaped, or non-functional esophagus where repeated myotomy failure has occurred. Transhiatal or minimally invasive esophagectomy with gastric conduit reconstruction is the most definitive surgical option in this setting.

Pharmacological therapy: Long-acting nitrates (isosorbide dinitrate) and calcium channel blockers (nifedipine) reduce LES pressure modestly but have significant side effect profiles. Efficacy is inferior to all procedural therapies. Use is limited to symptom bridging before definitive treatment or palliation in medically frail patients.